BLB-101

BLB-101 refers to at least two distinct investigational drugs in development by different companies for separate indications: 1. **Baylink Biosciences' BLB-101** is a preclinical antibody-drug conjugate (ADC) designed to target Claudin 6 (CLDN6) and Claudin 9 (CLDN9), tight junction proteins highly expressed in certain cancers such as ovarian, endometrial, and non-small cell lung cancer. The ADC delivers the topoisomerase 1 inhibitor exatecan using a proprietary hydrophilic linker with a high drug-to-antibody ratio, aiming for efficient tumor cell killing while sparing normal tissues[3][5]. This candidate is currently in preclinical development for CLDN6/9-positive tumors. 2. **Blue Lake Biotechnology's BLB-101** is an intranasal vaccine candidate targeting SARS-CoV-2, the virus responsible for COVID-19. It acts as an immunostimulant and SARS-CoV-2 spike protein inhibitor and is currently in Phase II clinical trials for COVID-19[1][2]. Blue Lake Biotechnology specializes in novel human vaccines. 3. **Beijing Libang Biomedicine's BLB-101** appears to be a biological product developed primarily for neoplasms including CD19-positive B-cell precursor acute lymphoblastic leukemia; its highest reported R&D status is IND approval[4].